Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Free Cash Flow: 2021-2024

Historic Free Cash Flow for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$167.8 million.

  • Amylyx Pharmaceuticals' Free Cash Flow rose 26.86% to -$30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.5 million, marking a year-over-year decrease of 61.66%. This contributed to the annual value of -$167.8 million for FY2024, which is 1671.49% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Free Cash Flow of -$167.8 million as of FY2024, which was down 1,671.49% from $10.7 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Free Cash Flow's 5-year high stood at $10.7 million during FY2023, with a 5-year trough of -$182.4 million in FY2022.
  • Its 3-year average for Free Cash Flow is -$113.2 million, with a median of -$167.8 million in 2024.
  • In the last 5 years, Amylyx Pharmaceuticals' Free Cash Flow spiked by 105.85% in 2023 and then slumped by 1,671.49% in 2024.
  • Amylyx Pharmaceuticals' Free Cash Flow (Yearly) stood at -$75.2 million in 2021, then tumbled by 142.70% to -$182.4 million in 2022, then surged by 105.85% to $10.7 million in 2023, then slumped by 1,671.49% to -$167.8 million in 2024.